Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Doumas

Showing results (1-10 of 379) with videos related to

Pageof 38
Sort By:
Current Vascular Pharmacology|August 3, 2013
Editorial: interventional management of hypertension and cardiovascular disease: the beginning of a new era?Michael Doumas
Endocrinology and Metabolism (Seoul, Korea)|July 27, 2021
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational StudiesDimitrios Patoulias, Michael Doumas
Journal of Hypertension|October 16, 2008
Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complicationsAthanasios Manolis, Michael Doumas
Lancet (London, England)|November 25, 2010
Renal sympathetic denervation: the jury is still outMichael Doumas, Stella Douma
The New England Journal of Medicine|January 16, 2009
Telmisartan for prevention of cardiovascular eventsMichael Doumas, Vasilios Papademetriou
Clinical and Molecular Hepatology|September 24, 2020
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?Dimitrios Patoulias, Michael Doumas
European Journal of Internal Medicine|June 17, 2022
Conservative versus aggressive blood pressure reduction: Do we have a winner?Dragan Lovic, Michael Doumas
Current Vascular Pharmacology|January 8, 2021
Emerging Cardiovascular Risk Factors and Specific Patient Populations at Increased Cardiovascular RiskNiki Katsiki, Michael Doumas
Diabetes & Metabolism Journal|January 6, 2020
Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (<i>Diabetes Metab J</i> 2019:43:711-7)Dimitrios Patoulias, Michael Doumas
Journal of Hypertension|January 9, 2020
Atrial fibrillation, arterial hypertension, and primary aldosteronism: a dangerous and unexpected trioAthanasios Manolis, Michael Doumas
Pageof 38

Showing results (1-10 of 379) with videos related to

Sort By:
Pageof 38
Current Vascular Pharmacology|August 3, 2013
Editorial: interventional management of hypertension and cardiovascular disease: the beginning of a new era?Michael Doumas
Endocrinology and Metabolism (Seoul, Korea)|July 27, 2021
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational StudiesDimitrios Patoulias, Michael Doumas
Journal of Hypertension|October 16, 2008
Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complicationsAthanasios Manolis, Michael Doumas
Lancet (London, England)|November 25, 2010
Renal sympathetic denervation: the jury is still outMichael Doumas, Stella Douma
The New England Journal of Medicine|January 16, 2009
Telmisartan for prevention of cardiovascular eventsMichael Doumas, Vasilios Papademetriou
Clinical and Molecular Hepatology|September 24, 2020
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?Dimitrios Patoulias, Michael Doumas
European Journal of Internal Medicine|June 17, 2022
Conservative versus aggressive blood pressure reduction: Do we have a winner?Dragan Lovic, Michael Doumas
Current Vascular Pharmacology|January 8, 2021
Emerging Cardiovascular Risk Factors and Specific Patient Populations at Increased Cardiovascular RiskNiki Katsiki, Michael Doumas
Diabetes & Metabolism Journal|January 6, 2020
Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (<i>Diabetes Metab J</i> 2019:43:711-7)Dimitrios Patoulias, Michael Doumas
Journal of Hypertension|January 9, 2020
Atrial fibrillation, arterial hypertension, and primary aldosteronism: a dangerous and unexpected trioAthanasios Manolis, Michael Doumas
Pageof 38